Welcome to our dedicated page for EUDA Health Holdings SEC filings (Ticker: EUDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
EUDA Health Holdings Limited filings document the company as a Nasdaq-listed foreign private issuer operating a Singapore-based healthcare business focused on non-invasive, preventive and longevity-oriented services in Asia. Form 6-K reports disclose business updates involving stem cell and cellular therapy arrangements, commercial distribution rights, and related healthcare platform expansion.
The filing record also covers capital-structure and governance matters, including ordinary share offerings under a Form F-3 registration statement, warrant issuances, amendments, repurchase and cancellation, a reverse stock split, Nasdaq market-value compliance notices, and amendments to the company's BVI constitutional documents.
EUDA Health Holdings Ltd Schedule 13G reports that Zhang Xin beneficially owns 295,000 ordinary shares, representing 9.85% of the class. The filing states shares outstanding were 2,994,325 ordinary shares as of May 22, 2026.
The filing lists sole voting and sole dispositive power over the 295,000 shares. The document is a passive ownership disclosure under Schedule 13G and does not describe transactions or transfers within the excerpt.
EUDA Health Holdings Limited has expanded its Helixé product line with the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask, a premium beauty mask developed by Chemokine Pte Ltd. EUDA holds exclusive global distributorship rights for Helixé products from Chemokine.
The Regenixé Mask uses iPSC-derived skin stem cell secretome and cellulose mask technology, aimed at supporting skin hydration, brightening, and overall recovery. EUDA plans to leverage its existing distribution networks and wellness partnerships in Malaysia and China to drive sales across the Asia-Pacific region.
Management cites industry research indicating the global face mask market could reach about US$9.08 billion by 2031, with Asia-Pacific as a leading region. This launch aligns with EUDA’s broader strategy in non-invasive, preventive healthcare and longevity-focused consumer products in Asia.
EUDA Health Holdings Limited has expanded its Helixé product line with the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask, a premium beauty mask developed by Chemokine Pte Ltd. EUDA holds exclusive global distributorship rights for Helixé products from Chemokine.
The Regenixé Mask uses iPSC-derived skin stem cell secretome and cellulose mask technology, aimed at supporting skin hydration, brightening, and overall recovery. EUDA plans to leverage its existing distribution networks and wellness partnerships in Malaysia and China to drive sales across the Asia-Pacific region.
Management cites industry research indicating the global face mask market could reach about US$9.08 billion by 2031, with Asia-Pacific as a leading region. This launch aligns with EUDA’s broader strategy in non-invasive, preventive healthcare and longevity-focused consumer products in Asia.
EUDA Health Holdings Limited reported that it has regained compliance with the Nasdaq Capital Market’s continued listing requirements related to market value. Nasdaq had previously notified EUDA on April 23, 2026 that its Market Value of Listed Securities was below the required $35 million for 32 consecutive business days under Nasdaq Listing Rule 5550(b)(2). A subsequent Nasdaq notice on May 28, 2026 confirmed that EUDA’s Market Value of Listed Securities was $35 million or greater for ten consecutive business days from May 13 to May 27, 2026, restoring the Company’s compliance with the MVLS standard.
EUDA Health Holdings Limited reported that it has regained compliance with the Nasdaq Capital Market’s continued listing requirements related to market value. Nasdaq had previously notified EUDA on April 23, 2026 that its Market Value of Listed Securities was below the required $35 million for 32 consecutive business days under Nasdaq Listing Rule 5550(b)(2). A subsequent Nasdaq notice on May 28, 2026 confirmed that EUDA’s Market Value of Listed Securities was $35 million or greater for ten consecutive business days from May 13 to May 27, 2026, restoring the Company’s compliance with the MVLS standard.
EUDA Health Holdings Limited filed a Form F-3 prospectus to register for resale up to 947,963 ordinary shares, consisting of 500,000 shares issued under a SAFT with QB Limited, 440,657 shares held by affiliates and 7,306 Warrant Shares issuable upon exercise of 292,250 warrants. The company will not receive proceeds from sales by the selling shareholders. The prospectus states 2,994,325 ordinary shares outstanding as of May 22, 2026 and discloses a Nasdaq MVLS deficiency (requirement: $35,000,000) with an April 23, 2026 notice and an October 20, 2026 cure deadline.
The filing also discloses going-concern commentary (net loss $2.8M in 2025, cash ~$0.3M, negative working capital ~$4.8M as of December 31, 2025), identification of a material weakness in internal control, and plans to register resale of shares issued under a token SAFT. The registration permits the listed selling shareholders to resell their shares from time to time; timing and amounts are at the selling shareholders’ discretion.
EUDA Health Holdings Limited filed a Form 6-K highlighting that Shenzhen Inno Immune Co., Ltd. has received official approval under the 2025 Shenzhen Key Industry R&D Program for a TCR-T cell therapy project targeting solid tumors.
The project is scheduled to run from January 1, 2026 to December 31, 2028 and may receive up to approximately US$434,688 in government funding from the Shenzhen Science and Technology Innovation Bureau. Under a non-exclusive distribution arrangement, EUDA holds rights to market and sell selected Shenzhen Inno immunotherapies to customers in Malaysia via its subsidiary CK Health Plus Sdn Bhd, with treatments conducted in China.
Management explains that this aligns with EUDA’s strategy to expand access to advanced, science-driven therapies and supports its broader focus on preventive and longevity-focused healthcare across Asia.
EUDA Health Holdings Limited files its annual Form 20-F for the year ended December 31, 2025, highlighting ongoing financial strain and strategic shifts. The company reports a net loss of approximately $2.8 million for 2025, following a $15.4 million loss in 2024, and discloses a working capital deficit of about $4.8 million with only $0.3 million in cash.
EUDA’s auditor raises substantial doubt about its ability to continue as a going concern, and management acknowledges material weaknesses in internal control over financial reporting. Nasdaq has notified the company that it failed to maintain the required $35 million Minimum Market Value of Listed Securities; EUDA must regain compliance by October 20, 2026 to avoid potential delisting.
The report describes a strategic move from medical services to wellness, including the $15.0 million all-share acquisition of CK Health, which generated roughly $2.0 million of 2025 revenue, and reliance on Southeast Asian wellness and planned stem cell offerings. EUDA also details multiple equity and convertible financings, a 1-for-20 reverse stock split, and an agreement to purchase 16 million QB utility tokens using cash and shares, underscoring its need for ongoing external funding.
EUDA Health Holdings Limited reported that Nasdaq notified the company on April 23, 2026 that it failed to maintain the required Minimum Market Value of Listed Securities of $35 million for 32 consecutive business days under Nasdaq Listing Rule 5550(b)(2). The notice does not immediately affect trading, and EUDA has 180 calendar days, until October 20, 2026, to regain compliance by having its market value close at $35,000,000 or more for at least ten consecutive business days. If EUDA does not regain compliance within this period, its securities will be subject to potential delisting, although the company would have the right to appeal.
EUDA Health Holdings Limited approved and is implementing a 1-for-20 reverse stock split of its ordinary shares, effective at market open on March 23, 2026 on the Nasdaq Capital Market. The company states that shareholder ownership percentages and voting power will remain substantially the same aside from minor rounding effects.
Shares outstanding will be reduced from approximately 50,307,491 to approximately 2,515,375, with fractional shares rounded up and no cash paid in lieu. EUDA’s outstanding warrants will be adjusted proportionately, cutting underlying shares from about 4,458,625 to about 222,932 while increasing the exercise price from $11.50 to $230.00 per share equivalent.
EUDA Health Holdings Ltd Chief Financial Officer Tay Whye Shin has filed an initial Form 3, which is a required statement of beneficial ownership for company insiders. The filing establishes this officer’s reporting status under SEC rules but does not report any stock transactions.
EUDA Health Holdings Ltd director Liew Kwong Yeow filed an initial ownership report showing direct holdings of 3,000 Ordinary Shares. This Form 3 does not report any recent buy or sell transactions; it simply establishes his current equity stake in the company.